Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Restricted Stock Units | 15.8K | $1.19M | $75.18 | Feb 27, 2024 | Direct |
Axsome Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Employee Stock Option (Right to Buy) | 28.7K | Feb 27, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AXSM | Axsome Therapeutics, Inc. | Feb 27, 2024 | 2 | $0 | 4 | Feb 29, 2024 | CHIEF FINANCIAL OFFICER |
AXSM | Axsome Therapeutics, Inc. | Mar 2, 2023 | 2 | $0 | 4 | Mar 6, 2023 | CHIEF FINANCIAL OFFICER |
AXSM | Axsome Therapeutics, Inc. | Mar 4, 2022 | 2 | $0 | 4 | Mar 8, 2022 | CHIEF FINANCIAL OFFICER |
AXSM | Axsome Therapeutics, Inc. | Nov 18, 2021 | 4 | $33.7K | 4 | Nov 22, 2021 | CHIEF FINANCIAL OFFICER |
AXSM | Axsome Therapeutics, Inc. | Nov 12, 2021 | 1 | $0 | 4 | Nov 15, 2021 | CHIEF FINANCIAL OFFICER |